文献速递肾癌与肾肿瘤

肾细胞癌的外科转移灶切除术:一项系统综述

Surgical Metastasectomy in Renal Cell Carcinoma: A Systematic Review.
PubMed 文献 · Eur Urol Oncol · 2018-09-24

该系统综述纳入56项回顾性研究,评估外科转移灶切除术(SM)在转移性肾细胞癌(mRCC)中的作用。接受SM者中位总生存期为36至142个月,未接受SM者为8至27个月;SM与较低的全因死亡风险相关(汇总校正风险比2.37,95%置信区间2.03-2.87;p<0.001)。完全切除转移灶是最重要的总生存预后因素。

要点

  • 接受SM者中位总生存期36至142个月,未接受SM者为8至27个月。
  • SM与较低全因死亡风险相关:汇总校正风险比2.37(95%CI 2.03-2.87;p<0.001)。
  • 完全切除转移灶是总生存的最重要预后因素,肺转移灶切除似乎生存获益最佳。

核心结论

  • 尽管无随机临床数据,已发表研究支持SM在现代背景下用于经选择的患者。
  • 完全SM可使患者获得免于全身治疗的持续生存。
  • 将SM与全身治疗整合为多模式方案对部分患者仍是有效选择。

研究设计与样本

  • 系统检索Embase和Medline数据库,对SM在mRCC中的作用进行系统综述。
  • 最终纳入56项研究进行证据合成,所有纳入研究均为回顾性研究且多为非对照研究。

主要发现

  • 接受SM者中位总生存期为36至142个月,未接受SM者为8至27个月。
  • SM与较低的全因死亡风险相关(汇总校正风险比2.37,95%置信区间2.03-2.87;p<0.001)。
  • SM与原发肿瘤手术的并发症发生率和死亡率相似。
  • 总生存的最重要预后因素为转移灶完全切除;其他预后因素包括肾切除术后的无病生存期、原发肿瘤特征(T分期≥3、高级别、肉瘤样特征和病理淋巴结状态)、转移灶数目和体能状态。
  • 肺转移灶切除似乎显示出最佳的生存获益。

临床怎么用

  • 作者认为,对于转移灶数目有限且一般健康状况良好的经选择患者,该策略是一种选择。
  • 作者认为,当可实现完全切除时,外科切除肾细胞癌来源的转移灶可能有助于延长生存并避免全身治疗。

局限性

  • 缺乏关于SM在全身治疗时代生存获益作用的高级别证据。
  • 所有纳入研究均为回顾性研究且多为非对照研究。
  • 无随机临床数据可用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: The benefit of surgical metastasectomy (SM) for patients with metastatic renal cell carcinoma (mRCC) remains controversial because of the lack of high-level evidence on the role of SM in terms of survival benefit in the era of systemic therapy. OBJECTIVE: To perform a systematic review of the literature on the role of SM in the treatment of mRCC and discuss key issues in the SM decision-making process. EVIDENCE ACQUISITION: A systematic search of the Embase and Medline databases was carried out and a systematic review of the role of SM in mRCC was performed. A total of 56 studies were finally included in the evidence synthesis. EVIDENCE SYNTHESIS: All the studies included were retrospective and mostly noncomparative. Median overall survival (OS) ranged from 36 to 142mo for those undergoing SM, compared to 8-27mo for no SM. SM was associated with a lower risk of all-cause mortality compared to no SM (pooled adjusted hazard ratio 2.37, 95% confidence interval 2.03-2.87; p<0.001). Morbidity and mortality were similar for SM and primary tumor surgery. The most important prognostic factor for OS was complete resection of metastases. Other prognostic factors included disease free-survival from nephrectomy, primary tumor features (T stage ≥3, high grade, sarcomatoid features, and pathological nodal status), the number of metastases, and performance status. Lung metastasectomy seemed to show the best survival benefit. CONCLUSIONS: Although no randomized clinical data are available, published studies support the role of SM in selected patients in the modern era. Complete SM allows sustained survival free of systemic treatment. Integration of SM and systemic therapy in a multimodal approach remains a valid option for some patients. PATIENT SUMMARY: Surgical resection of metastases originating from renal cell carcinoma may play a role in prolonging survival and avoiding systemic therapy when complete resection is achievable. This strategy is an option for selected patients with a limited number of metastases who still have good general health status.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Ouzaid I, Capitanio U, Staehler M, et al. Surgical Metastasectomy in Renal Cell Carcinoma: A Systematic Review. Eur Urol Oncol. 2018. PMID: 31017089. doi:10.1016/j.euo.2018.08.028

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。